# A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients

> **NCT04177290** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Advanced or Metastatic NSCLC

## Interventions

- **DRUG:** Sintilimab (M1b)
- **DRUG:** Sintilimab (approved)

## Key facts

- **NCT ID:** NCT04177290
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-02
- **Primary completion:** 2021-02-28
- **Final completion:** 2022-09-04
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04177290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04177290, "A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04177290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*